Uniqure Plummets 59% On A 'Confusing' And 'Unexpected' Twist For Its Gene Therapy

investors.com/news/technology/uniqure-stock-huntingtons-gene-therapy-fda-feedback

stock crashed Monday on "confusing" and "unexpected" feedback from the Food and Drug Administration for its Huntington's disease gene therapy.
The company "believes that the FDA currently no longer agrees that the data from the Phase I/II studies of AMT-130 in comparison to an external…

This story appeared on investors.com, 2025-11-03 16:18:22.863000.
The Entire Business World on a Single Page. Free to Use →